Shopping Cart

No products in the cart.

17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

6-8 December 2024

Marriott Georgetown WASHINGTON DC, USA 

Join researchers, clinicians, academic experts, investigators and industry leaders to advance research, education and foster collaboration in person about both basic science and clinical pathways. A unique opportunity to contribute to a fast evolving field, to share your latest research, network with international experts and create lasting impact in the lives of patients worldwide.

Seating is limited to 350 attendees. Save your seat now and register 

About the Conference

The International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders (SCWD) is an annual high-level congress hosted by SCWD, a non-profit scientific organization in partnership with leading research institutes. Our mission is to bring together experts from around the globe to share insights, research, and innovative ideas related to sarcopenia, cachexia and wasting disorders, fostering collaboration and knowledge exchange across various disciplines.

Exploring Cachexia, Sarcopenia and Wasting disorders

Uniting Global Experts: Advancing Research and Collaboration

We are delighted to invite you to the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders (SCWD), taking place in Washington DC, USA, at the Marriott Georgetown, from December 6-8, 2024. The conference will be chaired by Professor Stefan Anker (Berlin, Germany) and Professor Jeffrey Crawford (Durham, USA).

The SCWD Board is committed to providing an exceptional experience that meets the needs of our global community. The conference aims to:

  • Foster in-person connections and collaboration among the cachexia and sarcopenia communities;
  • Share the latest advancements in research and treatment;
  • Offer accessible virtual options for remote participation through a digital interactive platform;
Picture of Prof. Stefan Anker (President, SCWD)
Prof. Stefan Anker (President, SCWD)
Picture of Prof. Jeffrey Crawford
Prof. Jeffrey Crawford

Register Now!

Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.

Our Valued Sponsors in 2023

Supporting SCWD's Mission to Advance Medical Research

The 16th international Conference of the Society on Cachexia, Sarcopenia & Muscle Wasting, will take place on 17-19 June 2023 in Stockholm, Sweden, under the guidance of Chairs of the SCWD, Professor Stefan Anker (Berlin, Germany) and Professor Gianluigi Savarese (Stockholm, Sweden).
To make sure the international community around the world keeps abreast with the latest advancements after the challenging COVID 19 pandemic and the recent events in Eastern Europe, the Board of the SCWD is determined to create the best possible conditions for the cachexia and sarcopenia community to meet in person. SCWD will also make sure highlights of the conference are accessible with virtual options to attend remotely via our digital interactive platform.
Abstract submission will open on December. Please visit our website regularly for updates.
We hope to see you in Stockholm and look forward to working with you again to continue the tradition of a mutually rewarding and intellectually stimulating SCWD conference!

The beauty of #SCWD22 being hybrid in-person & online is that hopefully I can catch up with the ones I miss later!”

Neysa Vaughan, Med Educator/Cancer Cachexia Researcher

“A superb conference for staying abreast of the latest therapeutic advancements in cachexia and sarcopenia, presented by esteemed experts.”

“An outstanding gathering showcasing cutting-edge research and innovations in the field of cachexia and sarcopenia


More Than 63 International Speakers in 2023

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!

Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. Guided by its core values of quality, respect, and integrity, by its track record of over forty years of commercial execution, and by its commitment to extending and improving the lives of cancer patients globally, Helsinn is the partner of choice for the biotech and pharma sector. With its leading position in cancer supportive care and strong focus in oncology and rare diseases, Helsinn is able to reach patients worldwide through its integrated CMC/manufacturing/supply and commercial platform complemented by scientific and technological expertise.

Helsinn has a commercial presence in 190 countries either directly, with its operating subsidiaries in the U.S. and China, or via its network of over forty long-standing trusted partners who share the same vision and values. The fully integrated supply chain and product development provided through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd., which cater to specific customer needs, are among the key services Helsinn offers its partners.

The Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Sustainability is at the heart of everything it does, which is reinforced in the company’s strategic plan by a commitment to sustainable growth.

To learn more about Helsinn please visit and follow us on Twitter and LinkedIn